Abstract:The TRPA1 and TRPV1 receptors are important pharmaceutical targets for antipruritic and analgesic therapy. Obtaining further knowledge on their roles and interrelationship in humans is therefore crucial. Preclinical results are contradictory concerning coexpression and functional interdependency of TRPV1 and TRPA1, but no human evidence exists. This human experimental study investigated whether functional responses from the subpopulation of TRPA1 nociceptors could be evoked after defunctionalization of TRPV1 nociceptors by cutaneous application of high-concentration capsaicin. Two quadratic areas on each forearm were randomized to pretreatment with an 8% topical capsaicin patch or vehicle for 24 hours. Subsequently, areas were provoked by transdermal 1% topical capsaicin (TRPV1 agonist) or 10% topical allyl isothiocyanate ("AITC," a TRPA1 agonist), delivered by 12 mm Finn chambers. Evoked pain intensities were recorded during pretreatments and chemical provocations. Quantitative sensory tests were performed before and after provocations to assess changes of heat pain sensitivity. Imaging of vasomotor responses was used to assess neurogenic inflammation after the chemical provocations. In the capsaicin-pretreated areas, both the subsequent 1% capsaicin- and 10% AITC-provoked pain was inhibited by 92.9 ± 2.5% and 86.9 ± 5.0% (both: P < 0.001), respectively. The capsaicin-ablated skin areas showed significant heat hypoalgesia at baseline (P < 0.001) as well as heat antihyperalgesia, and inhibition of neurogenic inflammation evoked by both 1% capsaicin and 10% AITC provocations (both: P < 0.001). Ablation of cutaneous capsaicin-sensitive afferents caused consistent and equal inhibition of both TRPV1- and TRPA1-provoked responses assessed psychophysically and by imaging of vasomotor responses. This study suggests that TRPA1 nociceptive responses in human skin strongly depend on intact capsaicin-sensitive, TRPV1 fibers.

Transient receptor potential vanilloid 1 as a therapeutic target in analgesia

TRPV1-Targeted Drugs in Development for Human Pain Conditions

Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field

Endocannabinoid activation of the TRPV1 ion channel is distinct from activation by capsaicin

Activation of TRPV1 by Capsaicin Analogs with a Shorter or Longer Neck

A Novel Approach to Pain Therapy: Development of Transient Receptor Potential Vanilloid 1 Antagonists

Targeting TRP channels for pain relief: A review of current evidence from bench to bedside

Current insights and therapeutic strategies for targeting TRPV1 in neuropathic pain management

The Functional Regulation of TRPV1 and Its Role in Pain Sensitization.

Progress in the development of TRPV1 small-molecule antagonists: Novel Strategies for pain management

TRPV1 Channels in the Central Nervous System as Drug Targets

The Mysteries of Capsaicin-Sensitive Afferents

Ablation of TRPV1+ Afferent Terminals by Capsaicin Mediates Long-Lasting Analgesia for Trigeminal Neuropathic Pain

A "cute" desensitization of TRPV1

Unravelling the Mystery of Capsaicin: A Tool to Understand and Treat Pain

TRPV1: Receptor structure, activation, modulation and role in neuro-immune interactions and pain

Novel marine natural products as effective TRPV1 channel blockers

Psychophysical and vasomotor evidence for interdependency of TRPA1 and TRPV1-evoked nociceptive responses in human skin: an experimental study

Pharmacology Of Modality-Specific Transient Receptor Potential Vanilloid-1 Antagonists That Do Not Alter Body Temperature

Integrating TRPV1 Receptor Function with Capsaicin Psychophysics

Targeting TRPV1 for Cancer Pain Relief: Can It Work?